We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PD-1/PD-L1 Combination Therapy in Cancer Treatment
Whitepaper

PD-1/PD-L1 Combination Therapy in Cancer Treatment

PD-1/PD-L1 Combination Therapy in Cancer Treatment
Whitepaper

PD-1/PD-L1 Combination Therapy in Cancer Treatment

Cancer immunotherapy, especially the use of immune checkpoint inhibitors, has been successful in improving the treatment landscape of malignancies.

Programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) blockade therapy is a new class of anticancer immunotherapy that utilizes the body’s immune system to resist cancer and causes cancer cell death by blocking the PD-1/PD-L1 signaling pathway.

Download this whitepaper to learn more about PD-1/PD-L1: 

  • Blockade therapy resistance
  • Combination therapy with CTLA-4 blockers
  • Combination therapy with targeted drug EGFR
Advertisement